<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04055883</url>
  </required_header>
  <id_info>
    <org_study_id>DA1229_CAVD_II</org_study_id>
    <nct_id>NCT04055883</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate Efficacy and Safety of DA-1229 in Patients With CAVD</brief_title>
  <acronym>DIP-CAVD</acronym>
  <official_title>A Multicenter, Double-blind, Placebo-controlled, Stratified-randomized, Parallel, Therapeutic Exploratory Clinical Study to Evaluate the Efficacy and Safety of DA-1229 in Patients With Calcific Aortic Valve Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of DA-1229 in patients with calcific aortic
      valve disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>aortic valve calcium volume change</measure>
    <time_frame>96 weeks</time_frame>
    <description>aortic valve calcium volume change compared to baseline(mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>aortic valve calcium volume change</measure>
    <time_frame>48 weeks</time_frame>
    <description>aortic valve calcium volume change compared to baseline(mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aortic valve calcium score change</measure>
    <time_frame>48 weeks, 96 weeks</time_frame>
    <description>aortic valve calcium score change compared to baseline(AU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aortic valve calcium volume change percent</measure>
    <time_frame>48 weeks, 96 weeks</time_frame>
    <description>aortic valve calcium volume change percent compared to baseline(%)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Calcific Aortic Valve Disease</condition>
  <arm_group>
    <arm_group_label>DA-1229 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DA-1229 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DA-1229 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-1229</intervention_name>
    <description>All participants are administered one tablet per day for 96 weeks</description>
    <arm_group_label>DA-1229 10mg</arm_group_label>
    <arm_group_label>DA-1229 5mg</arm_group_label>
    <arm_group_label>DA-1229 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male and female subjects of ages in the range over 19

          -  The subjects whose echocardiography or heart CT result meets the criterion in the
             screening period or 4 weeks before screening visit

               -  Criterion : 2.0m/s ≤ peak aortic-jet velocity &lt; 4.0m/s or aortic valve calcium
                  score ≥300AU

          -  The subjects completely understood the clinical trial through detailed explanation
             presented, determined to participate in the clinical trial spontaneously, and agreed
             to observe precautions suggested thereby through written consent

        Exclusion Criteria:

          -  The cause of CAVD is niether degenerative nor bicuspid aortic valve

          -  The subjects who have other aortic valve disease as other clinically significant
             aortic insufficiency or mitral disease

          -  The subjects who had an aortic valve operation or are expected to need aortic valve
             operation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jae-Kwan Song, PhD</last_name>
    <phone>82-2-3010-3155</phone>
    <email>jksong@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae-Kwan Song, PhD</last_name>
      <phone>82-2-3010-3155</phone>
      <email>jksong@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Jae-Kwan Song, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>August 26, 2019</last_update_submitted>
  <last_update_submitted_qc>August 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

